|
gptkbp:instance_of
|
gptkb:DNA
|
|
gptkbp:administration_settings
|
home or clinical setting
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:clinical_trial
|
Phase III
ongoing studies
|
|
gptkbp:clinical_use
|
treatment of bleeding episodes
|
|
gptkbp:contraindication
|
known hypersensitivity to components
|
|
gptkbp:dosage_form
|
lyophilized powder
|
|
gptkbp:dosing_adjustments
|
based on body weight
|
|
gptkbp:drug_interactions
|
anticoagulants
|
|
gptkbp:duration
|
as needed
|
|
gptkbp:effective_date
|
gptkb:1993
FDA approved
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
powder for reconstitution
|
|
gptkbp:healthcare
|
injectable solution
hemophilia specialist
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kogenate
|
|
gptkbp:indication
|
prophylaxis of bleeding episodes
|
|
gptkbp:ingredients
|
gptkb:recombinant_factor_VIII
|
|
gptkbp:is_effective_against
|
effective in reducing bleeding
|
|
gptkbp:is_monitored_by
|
factor VIII levels
factor levels and bleeding episodes
|
|
gptkbp:label
|
FDA guidelines
|
|
gptkbp:manufacturer
|
gptkb:Baxter_International
|
|
gptkbp:market
|
adverse event reporting
|
|
gptkbp:mechanism_of_action
|
factor VIII replacement
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:patient_compliance
|
important for treatment success
|
|
gptkbp:patient_education
|
recognition of bleeding symptoms
|
|
gptkbp:patient_population
|
children and adults
|
|
gptkbp:pharmaceutical_class
|
gptkb:nuclear_weapons
|
|
gptkbp:pharmacokinetics
|
half-life of 12 hours
restores factor VIII levels
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
gptkb:National_Hemophilia_Foundation
individualized treatment plans
|
|
gptkbp:recommissioned
|
sterile water for injection
|
|
gptkbp:regulatory_compliance
|
marketed in multiple countries
|
|
gptkbp:research_focus
|
gene therapy alternatives
|
|
gptkbp:route_of_administration
|
intravenous
IV infusion
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:safety_measures
|
monitor for inhibitors
|
|
gptkbp:service_frequency
|
every 2 to 3 days
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
allergic reactions
thromboembolic events
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:supply_chain
|
managed by manufacturer
|
|
gptkbp:target_audience
|
patients with hemophilia A
|
|
gptkbp:therapeutic_category
|
gptkb:DNA
|
|
gptkbp:therapeutic_indications
|
surgical procedures
|
|
gptkbp:trade
|
Kogenate FS
|
|
gptkbp:treatment
|
improved quality of life
factor replacement therapy
prevent bleeding complications
|
|
gptkbp:type_of_care
|
critical for efficacy
|
|
gptkbp:used_for
|
gptkb:hemophilia_A
|
|
gptkbp:bfsParent
|
gptkb:Bayer
gptkb:Schering-Plough
|
|
gptkbp:bfsLayer
|
5
|